ImmunoGen IncNASDAQ:IMGN
- LAST PRICE4.68
- TODAY'S CHANGE (%)0.00 (0.00%)
- Bid / Lots4.58/ 5
- Ask / Lots4.70/ 5
- Open / Previous Close4.82 / 4.68
- Day Range
- 52 Week Range
- Volume2,449,985
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMGN |
|---|---|---|
| 09:32 ET | 41604 | 4.72 |
| 09:34 ET | 2760 | 4.8 |
| 09:36 ET | 14065 | 4.8168 |
| 09:38 ET | 16500 | 4.84 |
| 09:39 ET | 16079 | 4.81 |
| 09:41 ET | 4250 | 4.8099 |
| 09:43 ET | 11500 | 4.825 |
| 09:45 ET | 4063 | 4.81 |
| 09:48 ET | 5720 | 4.855 |
| 09:50 ET | 6224 | 4.84 |
| 09:52 ET | 10519 | 4.87 |
| 09:54 ET | 9837 | 4.845 |
| 09:56 ET | 9890 | 4.805 |
| 09:57 ET | 4700 | 4.81 |
| 09:59 ET | 16516 | 4.85 |
| 10:01 ET | 5179 | 4.81 |
| 10:03 ET | 7237 | 4.89 |
| 10:06 ET | 20322 | 4.91 |
| 10:08 ET | 23280 | 4.86 |
| 10:10 ET | 5370 | 4.86 |
| 10:12 ET | 6466 | 4.84 |
| 10:14 ET | 10705 | 4.8387 |
| 10:15 ET | 10373 | 4.85 |
| 10:17 ET | 10200 | 4.85 |
| 10:19 ET | 11898 | 4.83 |
| 10:21 ET | 7015 | 4.822 |
| 10:24 ET | 7717 | 4.82 |
| 10:26 ET | 9300 | 4.805 |
| 10:28 ET | 9823 | 4.805 |
| 10:30 ET | 36013 | 4.81 |
| 10:32 ET | 5625 | 4.815 |
| 10:33 ET | 4755 | 4.8299 |
| 10:35 ET | 11153 | 4.82 |
| 10:37 ET | 2000 | 4.8201 |
| 10:39 ET | 7108 | 4.83 |
| 10:42 ET | 1900 | 4.825 |
| 10:44 ET | 2600 | 4.8156 |
| 10:46 ET | 13530 | 4.8061 |
| 10:48 ET | 25997 | 4.8 |
| 10:50 ET | 43835 | 4.805 |
| 10:51 ET | 7000 | 4.805 |
| 10:53 ET | 11703 | 4.765 |
| 10:55 ET | 15076 | 4.7401 |
| 10:57 ET | 25795 | 4.735 |
| 11:00 ET | 16168 | 4.72 |
| 11:02 ET | 2794 | 4.7299 |
| 11:04 ET | 8013 | 4.71 |
| 11:06 ET | 12156 | 4.705 |
| 11:08 ET | 1830 | 4.71 |
| 11:09 ET | 4868 | 4.7 |
| 11:11 ET | 3400 | 4.71 |
| 11:13 ET | 7444 | 4.73 |
| 11:15 ET | 5089 | 4.745 |
| 11:18 ET | 7376 | 4.715 |
| 11:20 ET | 1000 | 4.72 |
| 11:22 ET | 13430 | 4.7013 |
| 11:24 ET | 10578 | 4.69 |
| 11:26 ET | 7745 | 4.67 |
| 11:27 ET | 16380 | 4.68 |
| 11:29 ET | 9210 | 4.675 |
| 11:31 ET | 16321 | 4.7016 |
| 11:33 ET | 7331 | 4.69 |
| 11:36 ET | 6664 | 4.71 |
| 11:38 ET | 8451 | 4.73 |
| 11:40 ET | 5523 | 4.71 |
| 11:42 ET | 2567 | 4.74 |
| 11:44 ET | 6169 | 4.71 |
| 11:45 ET | 5036 | 4.695 |
| 11:47 ET | 3596 | 4.695 |
| 11:49 ET | 3179 | 4.715 |
| 11:51 ET | 7012 | 4.71 |
| 11:54 ET | 7367 | 4.73 |
| 11:56 ET | 2300 | 4.715 |
| 11:58 ET | 4200 | 4.72 |
| 12:00 ET | 6137 | 4.715 |
| 12:02 ET | 2028 | 4.71 |
| 12:03 ET | 4108 | 4.69 |
| 12:05 ET | 7276 | 4.66 |
| 12:07 ET | 13560 | 4.665 |
| 12:09 ET | 7408 | 4.64 |
| 12:12 ET | 5099 | 4.635 |
| 12:14 ET | 6313 | 4.625 |
| 12:16 ET | 17512 | 4.6 |
| 12:18 ET | 5672 | 4.59 |
| 12:20 ET | 35675 | 4.57 |
| 12:21 ET | 13247 | 4.57 |
| 12:23 ET | 13493 | 4.595 |
| 12:25 ET | 13715 | 4.57 |
| 12:27 ET | 23648 | 4.6 |
| 12:30 ET | 5148 | 4.61 |
| 12:32 ET | 4050 | 4.58 |
| 12:34 ET | 9211 | 4.59 |
| 12:36 ET | 5578 | 4.5988 |
| 12:38 ET | 17533 | 4.605 |
| 12:39 ET | 6746 | 4.63 |
| 12:41 ET | 11077 | 4.62 |
| 12:43 ET | 7589 | 4.605 |
| 12:45 ET | 13712 | 4.58 |
| 12:48 ET | 13939 | 4.575 |
| 12:50 ET | 6546 | 4.575 |
| 12:52 ET | 27589 | 4.5684 |
| 12:54 ET | 10811 | 4.5699 |
| 12:56 ET | 16477 | 4.58 |
| 12:57 ET | 18276 | 4.59 |
| 12:59 ET | 18803 | 4.59 |
| 01:01 ET | 1645 | 4.5987 |
| 01:03 ET | 300 | 4.6 |
| 01:06 ET | 11532 | 4.59 |
| 01:08 ET | 5750 | 4.595 |
| 01:10 ET | 3985 | 4.585 |
| 01:12 ET | 10872 | 4.6 |
| 01:14 ET | 3000 | 4.6 |
| 01:15 ET | 5636 | 4.615 |
| 01:17 ET | 5400 | 4.615 |
| 01:19 ET | 16286 | 4.59 |
| 01:21 ET | 2200 | 4.595 |
| 01:24 ET | 3450 | 4.58 |
| 01:26 ET | 1425 | 4.58 |
| 01:28 ET | 3775 | 4.6 |
| 01:30 ET | 8254 | 4.59 |
| 01:32 ET | 3200 | 4.605 |
| 01:33 ET | 1400 | 4.6 |
| 01:35 ET | 10014 | 4.59 |
| 01:37 ET | 11171 | 4.59 |
| 01:39 ET | 1500 | 4.59 |
| 01:42 ET | 20517 | 4.615 |
| 01:44 ET | 2711 | 4.62 |
| 01:46 ET | 4606 | 4.61 |
| 01:48 ET | 1509 | 4.62 |
| 01:50 ET | 2350 | 4.62 |
| 01:51 ET | 8809 | 4.6 |
| 01:53 ET | 2257 | 4.605 |
| 01:55 ET | 2197 | 4.6 |
| 01:57 ET | 1700 | 4.61 |
| 02:00 ET | 5600 | 4.59 |
| 02:02 ET | 12591 | 4.605 |
| 02:04 ET | 500 | 4.605 |
| 02:06 ET | 4940 | 4.605 |
| 02:08 ET | 12090 | 4.63 |
| 02:09 ET | 6851 | 4.65 |
| 02:11 ET | 6551 | 4.655 |
| 02:13 ET | 8849 | 4.63 |
| 02:15 ET | 1590 | 4.62 |
| 02:18 ET | 4485 | 4.625 |
| 02:20 ET | 5769 | 4.635 |
| 02:22 ET | 3498 | 4.625 |
| 02:24 ET | 3700 | 4.6287 |
| 02:26 ET | 2782 | 4.62 |
| 02:27 ET | 6250 | 4.625 |
| 02:29 ET | 6466 | 4.62 |
| 02:31 ET | 6656 | 4.61 |
| 02:33 ET | 4250 | 4.605 |
| 02:36 ET | 2769 | 4.605 |
| 02:38 ET | 4701 | 4.6 |
| 02:40 ET | 5243 | 4.6 |
| 02:42 ET | 3800 | 4.62 |
| 02:44 ET | 5707 | 4.61 |
| 02:45 ET | 4228 | 4.605 |
| 02:47 ET | 3394 | 4.63 |
| 02:49 ET | 4370 | 4.62 |
| 02:51 ET | 11087 | 4.59 |
| 02:54 ET | 18610 | 4.56 |
| 02:56 ET | 11543 | 4.585 |
| 02:58 ET | 4500 | 4.61 |
| 03:00 ET | 10411 | 4.645 |
| 03:02 ET | 12457 | 4.64 |
| 03:03 ET | 2240 | 4.63 |
| 03:05 ET | 5746 | 4.62 |
| 03:07 ET | 3905 | 4.605 |
| 03:09 ET | 5196 | 4.61 |
| 03:12 ET | 2600 | 4.61 |
| 03:14 ET | 4091 | 4.6 |
| 03:16 ET | 11092 | 4.5901 |
| 03:18 ET | 4800 | 4.6 |
| 03:20 ET | 10076 | 4.605 |
| 03:21 ET | 11186 | 4.62 |
| 03:23 ET | 16319 | 4.64 |
| 03:25 ET | 7306 | 4.63 |
| 03:27 ET | 9027 | 4.62 |
| 03:30 ET | 9053 | 4.62 |
| 03:32 ET | 8286 | 4.62 |
| 03:34 ET | 7085 | 4.61 |
| 03:36 ET | 14534 | 4.62 |
| 03:38 ET | 5900 | 4.625 |
| 03:39 ET | 14042 | 4.625 |
| 03:41 ET | 4603 | 4.62 |
| 03:43 ET | 8052 | 4.62 |
| 03:45 ET | 13219 | 4.625 |
| 03:48 ET | 5280 | 4.63 |
| 03:50 ET | 11178 | 4.625 |
| 03:52 ET | 48926 | 4.655 |
| 03:54 ET | 45810 | 4.665 |
| 03:56 ET | 14841 | 4.665 |
| 03:57 ET | 47154 | 4.66 |
| 03:59 ET | 335998 | 4.68 |
May 29, 2020
BRIEF-Immunogen Presents Initial Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin® In Recurrent Ovarian Cancer
ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin(R) in Recurrent Ovarian Cancer, Regardless of Platinum Status
May 21, 2020
Thinking about buying stock in CleanSpark, IMV Inc, Canopy Growth Corp, ImmunoGen, or Chesapeake Energy Corp?
May 20, 2020
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
May 15, 2020
ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ImmunoGen Inc | 816.2M | --- | --- |
Codexis Inc | 733.0M | --- | --- |
Omeros Corp | 811.1M | --- | --- |
Quanterix Corp | 781.1M | --- | --- |
Athenex Inc | 887.3M | --- | --- |
MacroGenics Inc | 945.4M | --- | --- |
Company Information
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
Contact Information
- Headquarters
- 830 WINTER STWALTHAM, MA, United States 02451-1477
- Phone
- 781-895-0600
- Fax
- 781-895-0611
Executives
- Independent Chairman of the Board
- Stephen McCluski
- President, Chief Executive Officer, Director
- Mark Enyedy
- Senior Vice President and Chief Medical Officer
- Anna Berkenblit
- Senior Vice President - Regulatory Affairs and Quality
- Theresa Wingrove
- Vice President, Technical Operations
- Thomas Ryll
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $816.2M |
|---|---|
Revenue (TTM) | $87.0M |
Shares Outstanding | 174.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.30 |
EPS | $-0.58 |
Book Value | $-0.51 |
P/E Ratio | --- |
Price/Sales (TTM) | 9.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -85.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
